473 results about "Uric acid" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention discloses camel milk polypeptide with xanthine oxidase inhibitory activity and application thereof.The camel milk polypeptide is prepared by taking fresh camel milk as a raw material, conducting low-temperature centrifugation to remove fat, conducting triple enzymolysis through papain, pepsin and trypsin to obtain enzymatic hydrolysate, enabling the enzymatic hydrolysate to pass through an ultrafiltration membrane (the molecular weight cutoff is 10 kDa) to obtain filtrate, and conducting freeze-drying to obtain the camel milk polypeptide. The compound has xanthine oxidase inhibitory activity. The invention also discloses a small molecule polypeptide with xanthine oxidase inhibitory activity. The filtered solution is screened and combined with polypeptides by adopting a xanthine oxidase affinity ultrafiltration method, the activity of the polypeptides is verified through molecular docking and in-vitro enzyme inhibition, four small-molecule polypeptides with xanthine oxidase inhibitory activity are obtained, the sequence of the small-molecule polypeptides is shown as any one of SEQ ID NO.1-4, and the small-molecule polypeptides can be used for preparing drugs with the effect of inhibiting the uric acid level.

The invention provides a composite quality control liquid for an electrochemical multi-parameter detector. The composite quality control liquid comprises a buffer volume, a quality control substance and a stabilizer, the stabilizing agent comprises 5 to 50 g / L of bovine serum albumin, 0.1 to 10 g / L of EDTA-2Na (Ethylene Diamine Tetraacetic Acid), 10 to 100 g / L of a viscosity regulator, 0.3 to 25 g / L of a preservative and 5 to 20 g / L of a surfactant; the preparation method comprises the following steps: adding components of the stabilizer into a buffer system, preparing a preparation solution, preparing mother liquor of each quality control substance, proportionally mixing glucose mother liquor, uric acid mother liquor, beta-hydroxybutyric acid mother liquor and cholesterol sodium sulfate and triglyceride composite mother liquor according to the target concentration of the quality control solution, and fixing the volume by using the preparation solution to obtain the quality control liquid. And fully and uniformly mixing to obtain the composite quality control liquid. The composite quality control liquid can ensure that uric acid is not degraded, cholesterol triglyceride is not separated out, the formula is mild, and active substances in a detection system are not influenced.

A test strip for detecting uric acid in saliva that meets the requirement for room-temperature preservation, a preparation and detection method therefor and the use thereof. The test strip for detecting uric acid in saliva comprises a uricase, a peroxidase, a vitamin C oxidase, a bilirubin oxidase, a color developing agent, and a protective film coated on the test strip for detecting uric acid in saliva. To meet the needs of a target population for long-term monitoring and real-time tracking of changes in their uric acid levels, by means of agent addition, the test strip for detecting uric acid in saliva has prolonged preservation time at room temperature, enables non-invasive, efficient and convenient monitoring of a health status at any time, and timely detection and treatment, allows intuitive visual identification of uric acid levels in saliva by a subject, and meets the needs of a subject for long-term preservation at room temperature.

The invention discloses a siraitia grosvenorii instant coffee beverage assisting in reducing uric acid and a preparation method thereof, and belongs to the technical field of food based on the theory of homology of medicine and food. The coffee beverage is composed of instant coffee powder, a compound sweetening agent, coconut milk powder, milk powder and composite herbal powder in a specific proportion. The compound herbal powder is composed of poria cocos, peach kernels, dried tangerine or orange peel and momordica grosvenori which are selected from a medicinal and edible substance catalog. The herbal active ingredients and a coffee system are deeply fused by optimizing an extraction process, the dual regulation effects of inhibiting xanthine oxidase and promoting uric acid excretion are synergistically exerted, and the technical contradiction that common caffeine possibly affects uric acid excretion is effectively solved. The zebra fish in-vivo experiment proves that the level of uric acid can be remarkably reduced (Plt: 0.001), the improvement rate is as high as 17.63%, and a safe and effective daily diet intervention scheme is provided for people with hyperuricemia while the coffee flavor and convenience are provided.

The invention relates to the technical field of food sustained-release preparations, and particularly discloses a sour cherry powder sustained-release preparation with a stable uric acid reducing effect and a preparation process of the sour cherry powder sustained-release preparation. The sour cherry powder sustained-release preparation comprises a core active phase freeze-dried sour cherry powder, a sustained-release carrier phase, a synergistic function phase, an auxiliary regulation phase and a filler, the synergistic functional phase contains a celery seed extract, a curcumin-phospholipid complex, a prebiotic complex and the like, and all the components have a synergistic effect. The preparation method comprises the following steps: carrying out wall breaking, enzymolysis, purification and freeze-drying treatment on sour cherry fruits to obtain a core raw material, compounding the core raw material with other components, and carrying out slow-release carrier construction, coating granulation and other steps to prepare the microcapsule structure preparation. The preparation can be used for assisting in reducing the uric acid level, and has the advantages of high stability of active ingredients, continuous and stable uric acid reducing effect, consideration to intestinal health and the like; the preparation process adopts freeze-drying and micro-capsule coating technologies, effectively retains active ingredients, is controllable in operation, and is suitable for large-scale production.

The invention discloses a corn active peptide with effects of dispelling effects of alcohol, reducing uric acid and resisting oxidation, a preparation and application of the corn active peptide, and belongs to the technical field of biological active peptides. The amino acid sequence of the corn active peptide is at least one of LMFP, FEGLFR, FLR and QLPSYR. The corn active peptide with the effects of dispelling the effects of alcohol, reducing uric acid and resisting oxidation is separated from corn germ meal through enzymolysis, ultrafiltration and other technologies, amino acid sequence determination is conducted on the separated peptide fragments, screening is conducted in combination with the bioinformatics technology, and finally four peptide fragments are obtained. According to the present invention, the corn active peptides are identified, chemical synthesis is performed according to the identified peptide fragment sequence, the effects of alcohol effect dispelling, uric acid reducing and oxidation resistance of the synthesized single peptide fragment and the compounded peptide fragment are determined, and the corn active peptides have good XOD inhibition rate, good DPPH clearance rate and good ADH activation rate, and have important application prospects in the development of the products with effects of alcohol effect dispelling, uric acid reducing and oxidation resistance.

The application relates to the technical field of traditional Chinese medicines, in particular to a uric acid reducing composition and a preparation method thereof. The uric acid reducing composition comprises 35-45 parts of a cyclodextrin inclusion compound, 25-35 parts of nano-liposomes, 20-30 parts of a chicory extract-phospholipid complex and 5-8 parts of an antioxidant complex; the preparation method of the cyclodextrin inclusion compound comprises the following steps: step 1, adding beta-cyclodextrin into water, stirring and dissolving, adding pueraria extract, drying after inclusion reaction, and obtaining inclusion compound a; step 2, adding hydroxypropyl-gamma-cyclodextrin into water, stirring, adding mulberry leaf extract, drying after inclusion, and obtaining inclusion compound b; and step 3, mixing the inclusion compound a and the inclusion compound b, and obtaining the product. The uric acid reducing composition can more comprehensively and efficiently reduce blood uric acid level, and has high safety, high stability and high bioavailability. The preparation method is simple, easy to industrialize and beneficial to large-scale industrial production.

The invention provides a composite herbal cereal protein peptide solid beverage for targeted regulation of uric acid metabolism, and belongs to the technical field of common food developed from medicinal and edible raw materials. According to the invention, Chinese yam, mulberry leaf, gordon euryale seed, lily, coix seed, radish seed, root of kudzu vine, Poria cocos, dried orange peel and other raw materials listed in the catalog of substances which are both food and traditional Chinese medicinal materials in the prior art are carefully selected, and are prepared through scientific compatibility and modern technology. The product not only realizes multi-target reduction of uric acid by inhibiting generation of uric acid and promoting excretion of uric acid, but also is safe and free of toxic and side effects due to the fact that all the components conform to national food safety and medical and edible regulations. A zebra fish in-vivo experiment proves that the uric acid level can be remarkably reduced (Plt; 0.001) under the concentration of 500 mu g / mL. The invention provides a daily food solution integrating the traditional dietary therapy concept and modern scientific verification for people with hyperuricemia.

The invention relates to the technical field of medical biology, and discloses an application of a biomarker in the diagnosis of ejection fraction retention type heart failure, and the biomarker is kynuric acid. The biomarker is applied to preparation of a product for diagnosing or predicting ejection fraction retention heart failure. According to the method, the ejection fraction retention heart failure can be diagnosed by quantitatively detecting the kynuric acid in the plasma.

The invention relates to the technical field of traditional Chinese medicine compositions, and particularly discloses a uric-acid-reducing medicinal and edible composition containing giant salamander bone polypeptide and a preparation method of the uric-acid-reducing medicinal and edible composition. The uric acid-reducing medicinal and edible composition containing the giant salamander bone polypeptide comprises the giant salamander bone polypeptide and a traditional Chinese medicine compound extract, the traditional Chinese medicine compound extract is prepared by extracting the following raw materials through a dual solvent system of alcohol extraction and water extraction: folium mori, pawpaw, radix puerariae, rhizoma polygonati, rhizoma smilacis glabrae, yam rhizome, semen coicis, mulberry, cortex cinnamomi, endive, astragalus membranaceus, raw endothelium corneum gigeriae galli, fructus lycii, folium cortex eucommiae, rhizoma curcumae longae, agastache rugosus, folium perillae, fructus perillae, agkistrodon halys, semen euryales, Chinese yam, dandelion, mint, jujube, raw liquorice, honey-fried liquorice and pulp of dogwood fruit. The traditional Chinese medicine is prepared from hawthorn, sword bean, white hyacinth bean, plantain herb, dried rehmannia root and prepared rehmannia root. According to the application, the giant salamander bone polypeptide and the traditional Chinese medicine ingredients can play a stable and excellent synergistic effect in the medicinal and edible products, so that the medicinal and edible composition containing the giant salamander bone polypeptide and capable of reducing uric acid, which is relatively good in application quality, is obtained.

The invention relates to the technical field of glucometers, and discloses an intelligent multifunctional glucometer supporting data cloud storage and remote analysis, which comprises hardware, detection, data processing, wireless communication, a cloud server platform and an interactive terminal module to form a complete data closed loop. The hardware module is composed of an upper shell and a lower shell which are clamped, and the upper shell is provided with a detection port, an operation button and anti-skid lines. The detection module is integrated with an electrochemical sensor array and can synchronously detect blood glucose, uric acid, ketone body and blood fat. The data processing unit processes data in real time to generate a health report, and the wireless communication module supports multi-mode communication and encrypted transmission. The cloud platform stores data and outputs suggestions through machine learning, and the interactive terminal supports biological recognition and voice broadcast. The modules cooperate to realize multi-index detection, cloud analysis and intelligent interaction. The system has the advantages of multi-index synchronous detection, data security intelligent analysis and convenient interaction, and supports data cloud storage and remote analysis.

The invention relates to the technical field of microorganisms, in particular to enterococcus faecalis capable of degrading uric acid and application of the enterococcus faecalis, the enterococcus faecalis is named as Enterococcus faecalis SX3, and the preservation number of the enterococcus faecalis is CCTCC NO: M 2025248. The enterococcus faecalis has the advantages of being wide in antibacterial spectrum, rapid in growth, high in stress resistance, high in biological safety and the like, and important application value is provided for formulating a scheme for degrading uric acid.

The invention belongs to the field of preparation of medicaments for reducing uric acid, and particularly relates to a traditional Chinese medicine composition for reducing uric acid level and a preparation method thereof. Piperine, oat beta-glucan and medium chain triglyceride are mixed to react, a carrier material with a net structure is formed, a uric acid reducing solution obtained through adsorption and fermentation is freeze-dried, and the obtained efficient uric acid reducing component can remarkably and efficiently reduce the uric acid level in an organism; the regulating component is mixed with the metabolism promoting component obtained after powdering, the mixture is put into the coating material which can form a transparent film after being dried, and freeze spray drying is performed to obtain the long-acting agent which can stably play a role in a long-acting manner; the composition for maintaining stability and improving taste is uniformly sprayed on the surface of the traditional Chinese medicine component for reducing the uric acid level, and the prepared traditional Chinese medicine composition for reducing the uric acid level is remarkable and efficient in effect, improved in taste, free of peculiar smell, beneficial to persistent taking and free of irritation to liver and kidney after being taken for a long time.

The invention discloses a preparation method of hippocampus oil, which comprises the following steps: 1) adding dried hippocampus powder into a dichloromethane-methanol mixed solution, uniformly stirring, and extracting for 24 hours; 2) filtering the leach liquor, adding water, fully and uniformly mixing, standing for 12 hours, and collecting a lower layer organic phase; 3, the organic phase is subjected to rotary evaporation drying.The invention further discloses application of the hippocampus oil in preparation of uric acid lowering products.The hippocampus oil is rich in omega-3 polyunsaturated fatty acid (EPA and DHA), the activity of xanthine oxidase is moderately reduced, release of inflammatory factors is inhibited, and the comprehensive effect of inhibiting generation and relieving inflammation is achieved.

The invention belongs to the technical field of biological small molecule active peptides, and more specifically relates to a uric acid reducing active peptide, a preparation method and an application thereof. The uric acid reducing activity LQKW has remarkable XOD inhibitory activity, IC50 is 2.70 mg / mL, and the IC50 is superior to that of many known natural source XOD inhibitory peptides; good gastrointestinal digestion stability is shown, and the activity retention rate after in-vitro simulated gastrointestinal digestion is (61.84 + / -0.82)%. According to the invention, a specific binding mechanism of uric acid reduction activity and XOD active sites (Ile648, Phe649 and the like) is clarified through molecular docking, and a basis is provided for rational design based on a structure. According to the invention, the method for efficiently preparing the active peptide fragment from the white spirit vinasse is established, and the high-valued utilization of the wine brewing byproducts is realized. The uric acid reducing activity LQKW provided by the invention can be prepared through solid-phase synthesis, the process is mature, the quality is controllable, and a foundation is laid for industrialization. In addition, as the XOD inhibitor of a natural source, the uric acid reducing activity LQKW has good safety.

The invention provides construction of an electrochemical biosensor based on a fucoidin hydrogel microneedle and application of the electrochemical biosensor in online monitoring of uric acid, and relates to the technical field of biosensors. According to the micro-needle, Gantrez S-97 and PEG are subjected to copolymerization crosslinking to form a hydrogel main body, fucoidin is introduced for blending modification, a three-dimensional network structure is constructed by utilizing a high-temperature esterification reaction for regulating and controlling pH, and the super-expansion hydrogel micro-needle with high swelling property and good biocompatibility is formed. The microneedle can rapidly collect a skin interstitial fluid sample, and then through a screen printing electrode (SPE) platform, carboxylated MWCNTs are used for modifying an electrode and immobilizing uricase to construct an enzyme sensor. Hydrogen peroxide generated by catalyzing uric acid on the surface of the electrode participates in electrochemical reaction, and an output signal is used for real-time detection of uric acid concentration. The device integrates minimally invasive sampling and high-sensitivity electrochemical detection, has the advantages of quick response, simplicity and convenience in operation, good biocompatibility and the like, and is suitable for application scenes of continuous monitoring of uric acid, chronic disease management and the like.

The invention provides an application of beta-1, 3 / alpha-1, 3-glucan in preparation of a medicament with a uric acid reducing effect, and belongs to the field of medicaments. The food-grade beta-1, 3 / alpha-1, 3-glucan aims at solving the problems that in the prior art, uric acid lowering drugs are large in side effect and unstable in effect in an auxiliary mode, the food-grade beta-1, 3 / alpha-1, 3-glucan is provided, hypeluricemia is prevented or intervened, and the food-grade beta-1, 3 / alpha-1, 3-glucan is high in safety and wide in applicability.

The invention discloses a traditional Chinese medicine uric acid reducing preparation quality evaluation method and system based on big data, and relates to the technical field of traditional Chinese medicine preparation analysis. The quality evaluation method comprises the following steps: S1, acquiring chromatographic characteristic data, active ingredient content data and physical and chemical detection data, performing preprocessing, and constructing a preparation quality database; s2, carrying out consistency analysis through batch detection data of characteristic peaks, and dynamically optimizing a peak identification and correction strategy; s3, fusing the batch co-occurrence frequency, the distinction degree index and the inter-batch fluctuation which are subjected to correction processing, and performing characteristic peak screening through weighted operation; s4, performing multi-dimensional fusion quantitative evaluation by integrating a high-priority characteristic peak screening result, the effective component content data and the physical and chemical detection data; and S5, based on the multi-dimensional fusion evaluation result and historical sample data iterative training and abnormal mapping, parameter optimization and dynamic updating are realized. The problems of inter-batch feature drift and insufficient feature recognition precision of the traditional Chinese medicine uric acid reducing preparation in batch detection are solved.

The invention relates to the technical field of marine microorganisms, in particular to application of combined lactobacillus salivarius in preparation of products for improving metabolism of alcohol and uric acid, the combined lactobacillus salivarius NHNK-603 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2024416. Experiments show; the NHNK-603 has the effects of inhibiting the growth of klebsiella pneumoniae, inhibiting the production of alcohol, agglutinating the klebsiella pneumoniae, inhibiting the virulence gene of the klebsiella pneumoniae, promoting alcohol metabolism, reducing alcohol damage, tolerating alcohol, degrading uric acid, inhibiting the activity of xanthine oxidase, promoting uric acid excretion, promoting the proliferation of Alistipes indinctus and synthesizing hippuric acid; the thallus biofilm increases the function of colonization on mucoprotein and intestinal epithelial cells, and can be applied to preparation of products for improving metabolism of alcohol and uric acid.

The invention provides a medicinal and edible tea drink composition for assisting in reducing uric acid and a preparation method thereof, and belongs to the technical field of health-care food. The medicinal and edible tea drink composition for assisting in reducing uric acid comprises corn stigma, chicory, folium mori, fructus gardeniae, radix puerariae, fructus crataegi, semen coicis, poria cocos, rhizoma polygonati, pericarpium citri reticulatae and liquorice root. Cichorium intybus and folium mori are used as monarch drugs and synergistically inhibit the activity of xanthine oxidase; corn stigma and cape jasmine are used as ministerial drugs and have the effects of forcefully inducing diuresis and reducing the blood uric The radix puerariae can improve insulin resistance, the coix seeds and the poria cocos can tonify spleen and excrete dampness, and the rhizoma polygonati can tonify spleen and tonify kidney to treat both symptoms and root causes and serve as Hawthorn, pericarpium citri reticulatae and liquorice are used for regulating the medicine property and neutralizing the bitter taste, so that the consumer experience and compliance are greatly improved. The medicinal and edible tea drink composition achieves the effect of reducing uric acid through a multi-target and multi-path synergistic effect of inhibiting generation, promoting excretion and conditioning root.

The invention provides a composition for reducing uric acid and relieving gout and a preparation method thereof, and relates to the technical field of products for reducing uric acid and relieving gout. The composition comprises the following raw materials: 18-24 parts of phellinus igniarius, 9-13 parts of sunflower disc small molecule peptide extract, 3-7 parts of corn stigma, 4-6 parts of poria cocos, 2-5 parts of pawpaw, 3-6 parts of liquorice, 2-5 parts of astragalus extract and 3-6 parts of lettuce extract. The preparation method of the sunflower disc small-molecule peptide extract comprises the following steps: carrying out enzymolysis on sunflower disc powder twice, carrying out membrane filtration to obtain a sunflower disc small-molecule peptide solution, reacting the sunflower disc small-molecule peptide solution with chitosan oligosaccharide and transglutaminase, and carrying out freeze drying to obtain the sunflower disc small-molecule peptide extract. Through the proper raw material composition and proportion, the metabolic function can be effectively regulated to promote excretion of uric acid, so that the content of xanthine oxidase and adenosine deaminase in the liver is obviously reduced, the uric acid level is effectively reduced, the intestinal probiotic structure can be stabilized, the immunity is enhanced, the kidney is protected, and the good effects of reducing uric acid and relieving gout are achieved.

The invention provides a rare ginsenoside high-internal-phase Pickering emulsion microcapsule, a preparation method thereof and application of the rare ginsenoside high-internal-phase Pickering emulsion microcapsule in the aspects of uric acid reduction and kidney protection, and the preparation method comprises the following steps: (1) mixing a pectin aqueous solution and a tannic acid aqueous solution, adjusting the pH value, and stirring to obtain pectin-tannic acid composite sol, namely a water phase; (2) adding rare ginsenoside into the oil, and stirring to fully dissolve the rare ginsenoside to obtain an oil phase; (3) mixing the water phase and the oil phase, stirring, standing and carrying out ultrasonic treatment to obtain a crude emulsion; (4) emulsifying and homogenizing the crude emulsion to obtain crude emulsion; (5) carrying out high-pressure homogenization on the crude emulsion, so as to obtain a rare ginsenoside high-internal-phase Pickering emulsion; and (6) drying the rare ginsenoside high internal phase Pickering emulsion, so as to obtain the rare ginsenoside high internal phase Pickering emulsion microcapsule. The invention solves the problems of low safety, poor stability and low bioavailability of the traditional nano-emulsion, and belongs to the technical field of functional foods.

The invention provides a composition for reducing blood pressure, blood fat, blood sugar and uric acid and a preparation method thereof, the composition takes nine kinds of vegetable fat such as acer truncatum seed oil, tomato seed oil and the like as core raw materials, a composite antioxidant, phytosterol and xylooligosaccharide are supplemented, multiple-effect synergy is realized through scientific proportioning, and in the preparation process, the composition is free of toxic and side effects. And by adopting a step-by-step stirring technology, a nitrogen protection technology and a gradient ultrasonic homogenization technology, the biological activity of each component is effectively maintained. A plurality of in-vitro experiments and animal models verify that the composition can significantly regulate blood pressure, blood fat, blood sugar and uric acid levels through the synergistic effect of the raw materials. The raw materials are natural, the active ingredients are completely reserved, and the efficacy is stable, so that the functional health-care product has a wide application prospect in the field of functional health-care product development.

This invention discloses a natural plant extract anti-gout product, its preparation method, and its application. The natural plant extract anti-gout product comprises the following raw material components in parts by weight: acerola cherry powder: 10-30 parts, bellflower powder: 10-30 parts, celery seed powder: 10-30 parts, peppermint leaf extract: 1-10 parts, and vitamin C: 3-15 parts. The peppermint leaf extract is concentrated at a ratio of 10:1 to 20:1 and prepared using a low-temperature extraction process. Its efficacy is clear and comprehensive: breaking through the limitations of existing single-component supplements, it constructs a three-dimensional efficacy system of "uric acid regulation - anti-inflammatory and analgesic - blood pressure auxiliary regulation." The components work synergistically to quickly relieve acute gout pain, balance blood uric acid levels in the long term, and assist in regulating blood pressure, meeting the dual needs of people with gout and hypertension. This solves the problems of limited efficacy and insufficient consideration of comorbidities in existing technologies.

This invention discloses a near-infrared long-afterglow nanocomposite, its preparation, and its application in uric acid detection, belonging to the technical field of testing or analyzing materials by measuring their chemical or physical properties. The nanocomposite comprises a near-infrared long-afterglow luminescent center and an outer layer of organosilicon-doped mesoporous silicon containing tetrasulfide bonds. Under near-infrared light excitation, this nanocomposite exhibits excellent afterglow luminescence enhancement response to hydrogen peroxide. Since the product of uric acid decomposition by uricase is hydrogen peroxide, this composite enables highly sensitive and rapid detection of uric acid in blood. The composite provided by this invention has uniform particle size and high stability, effectively eliminating autofluorescence interference from biological components and improving detection accuracy.

This invention provides a traditional Chinese medicine composition, preparation method, and application for treating uric acid nephropathy, specifically belonging to the field of traditional Chinese medicine preparation technology. The traditional Chinese medicine composition of this invention comprises the following components in parts by weight: Aconitum carmichaelii 3-7 parts, Cinnamomum cassia 1-7 parts, Morinda officinalis 3-10 parts, Sinapis alba 3-9 parts, Fritillaria thunbergii 5-10 parts, Atractylodes lancea 3-9 parts, Coix lacryma-jobi 10-30 parts, Phellodendron chinense 3-12 parts, Pyrrosia lingua 6-15 parts, Dioscorea hypoglauca 9-15 parts, Smilax glabra 15-60 parts, and Prunus persica 5-10 parts. The traditional Chinese medicine composition of this invention can treat uric acid nephropathy, specifically including uric acid nephropathy of kidney yang deficiency type. It has a mild medicinal property, warms the kidney and invigorates the spleen, clears turbidity and detoxifies, and has no toxic side effects.

The application discloses an evaluation method for predicting the safety of EGFR TKIs monotherapy for NSCLC. The method comprises the following steps: obtaining the data of a plurality of patients receiving EGFR TKIs treatment; taking MDRAE (maximum grade of drug-related adverse event) as a safety index, constructing a safety evaluation final model, and the final model is an ordered logistic regression model, the covariates of the final model include normalized steady-state trough concentration, EGFR TKIs treatment history, gender, baseline glutamyltransferase, baseline uric acid, baseline creatine kinase, baseline platelets and baseline lymphocytes; obtaining the data of a target patient, inputting the numerical values of each covariate in the data of the target patient into the final model; determining the first probability of MDRAE of the target patient being grade 3 and above, the second probability of MDRAE being grade 2 and the third probability of MDRAE being grade 1 and below according to the final model, and taking the grade corresponding to the maximum probability in the three probabilities as the predicted grade of MDRAE of the target patient. The application improves the accuracy of predicting the safety of EGFR TKIs monotherapy for NSCLC.

The invention discloses antisense oligonucleotides for reducing XDH gene expression in a targeted manner and application of the antisense oligonucleotides, and belongs to the technical field of biological medicines. The antisense oligonucleotide mediates the degradation of the target mRNA through an RNase H (RNase H) dependent cleavage mechanism, and the mRNA expression of the XDH gene is horizontally knocked down after transcription; the antisense oligonucleotide molecule has a specific nucleic acid sequence, is combined with chemical modification design, can specifically bind XDH mRNA molecules in a targeting manner, promote XDH mRNA degradation and inhibit XDH protein synthesis, so that the expression level of XDH in cells is reduced, uric acid synthesis is reduced, the purpose of reducing uric acid is finally achieved, and cell experiments and animal model tests show that the antisense oligonucleotide molecule has a good application prospect. The antisense oligonucleotide molecule disclosed by the invention has a good uric acid reducing effect, and is long in drug effect duration and high in drug safety.

The present disclosure relates to uricase variant polypeptides and their multimers, as well as uricase conjugates comprising (i) a first domain comprising one of the uricase variant polypeptides conjugated to (ii) a second domain comprising a random coil polypeptide domain. Methods of using the uricase variant polypeptides and uricase conjugates to treat gout, tumor lysis syndrome, and other diseases associated with elevated uric acid levels in body fluids, including blood, are provided. Methods of recombinantly producing the uricase variant polypeptides and uricase conjugates disclosed herein are also provided.